Skip to content
value.today

Chimerix, Inc.

CMRXUnlisted company
$86 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$1 M
Dec-2021 ending year
value.today research
Net income
$-173 M
-17300.0% margin
value.today research
Employees
87
As on 2021
value.today research

Chimerix, Inc. in brief

Chimerix, Inc. is an unlisted company in the Biotechnology industry, based in North Carolina, USA. It was founded in 2000. In the year to Dec 2021 it had sales of $1 M and a net loss of $173 M. It employs about 87 people.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Chimerix, Inc.

Chimerix is a Biotechnology company committed to developing medicines to meaningfully improve the probability of survival for people facing deadly diseases. The company annual revenue is 5.37 million USD and 43 employees as on 2020. The headquarters is in USA.

Chimerix, Inc. timeline

2 events, 2000–2013
  1. 2000
  2. 🏁
    · approximate
    Founded
  3. 2013
  4. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of Chimerix, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Chimerix, Inc.

Acquisitions and changes
No longer listed: ticker CMRX is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).

Market cap history

$0 M$141 M$281 M$422 M$563 M20202021202220232024

World rank over time

▼ down 4,240 places since 2020
2020-01-01: #17934#17,93420202021-01-01: #13635#13,63520212022-01-07: #13185#13,18520222022-12-25: #19159#19,15920222023-07-30: #21508#21,50820232024-01-05: #22174#22,1742024

Rank in USA: #3,578 (Jan 2020) · #2,942 (Jan 2021) · #3,227 (Jan 2022) · #3,875 (Dec 2022) · #4,206 (Jul 2023) · #3,800 (Jan 2024)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
-17300.0%
Operating margin
—
Return on equity
-254.4%
Liabilities / assets
32.0%
Revenue per employee
$11 K
Profit per employee
$-2.0 M

Annual results

Revenue
$1 M
Operating income
—
Net income
$-173 M

Dec-2021 ending year

Balance sheet

Total assets
$100 M
Total liabilities
$32 M
Total equity
$68 M

Dec-2021 ending year

Markets and events: Chimerix, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2025-04-15
1.6 M
1 days to cover
Shares sold short, last 11 reportsAll stocks →

Trading halts

  • 2025-04-17 23:50 UTC, code D, resumed 04:00 UTC
  • 2025-03-05 11:55 UTC, code T3, resumed 12:30 UTC

Fails to deliver

  • : 124,944 shares at $8.54
  • : 325,644 shares at $8.55
  • : 93 shares at $8.52
  • : 64 shares at $8.51
  • : 241,701 shares at $8.53

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Lobbying by Chimerix, Inc.#

$170 K spent on lobbying the US Congress and federal agencies in 2022, most often on health issues.

Lobbying, 2022
$170 K
#942 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—
  • Health Issues3 reports

Lobbying firms hired in 2022

BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ /THE DASCHLE GROUP $170 K

Chimerix, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$170 K—4
2021$190 K—4
2020$200 K—4
2019$140 K—7
2018$130 K—7

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Chimerix, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Chimerix, Inc. compares in Biotechnology

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Chimerix, Inc.🇺🇸$86 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
Dec-2021 ending year
Balance sheet:
Dec-2021 ending year
Employees:
As on 2021
Profile updated:
Nov 14, 2026

Figures from value.today research.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Chimerix, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Chimerix, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Chimerix, Inc.? Suggest a correction